Comparative Pharmacology
Head-to-head clinical analysis: ERYTHROMYCIN STEARATE versus WYAMYCIN S.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ERYTHROMYCIN STEARATE versus WYAMYCIN S.
ERYTHROMYCIN STEARATE vs WYAMYCIN S
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Erythromycin is a macrolide antibiotic that binds to the 50S ribosomal subunit of susceptible bacteria, inhibiting protein synthesis by blocking the translocation of peptides.
WYAMYCIN S (tetracycline) inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, preventing the attachment of aminoacyl-tRNA to the mRNA-ribosome complex.
250-500 mg orally every 6 hours or 500-1000 mg orally every 12 hours; maximum 4 g/day.
WYAMYCIN S (clarithromycin/sulfamethoxazole) is a fixed-dose combination. Adult: 1 tablet (500 mg clarithromycin/800 mg sulfamethoxazole) orally every 12 hours for 7-14 days.
None Documented
None Documented
1.4-2 hours in adults with normal renal function; prolonged to 5-6 hours in anuria; unchanged in hepatic impairment.
2-3 hours in normal renal function; prolonged to 24-48 hours in end-stage renal disease.
Primarily excreted in bile as active drug; about 2-5% excreted renally as unchanged drug. Up to 15% excreted in feces.
Renal (90-95% unchanged via glomerular filtration) and biliary (<5%).
Category A/B
Category C
Macrolide Antibiotic
Macrolide Antibiotic